Last updated: August 1, 2026
Molindone hydrochloride is a mature, low-volume generic antipsychotic with limited commercial growth potential. Its U.S. market is defined by generic competition, narrow clinical use, low reimbursement value, and the absence of meaningful patent or regulatory exclusivity. Public sources do not disclose product-level revenue for molindone hydrochloride, and the drug is unlikely to represent material sales exposure for any diversified manufacturer.
What is molindone hydrochloride and how is it used?
Molindone hydrochloride is a first-generation antipsychotic in the dihydroindolone class. It was marketed in the United States under the brand name Moban for schizophrenia and related psychotic disorders. Its pharmacologic activity is primarily associated with dopamine D2 receptor antagonism.
| Attribute |
Molindone hydrochloride |
| Therapeutic class |
Typical antipsychotic |
| Primary historical indication |
Schizophrenia |
| Dosage form |
Oral tablets |
| Common strengths |
5 mg, 10 mg, 25 mg, 50 mg, and 100 mg historically marketed |
| FDA pathway |
Original NDA followed by generic ANDAs |
| Reference brand |
Moban |
| Current commercial position |
Mature generic product |
| Biosimilar exposure |
None |
| Patent position |
No commercially meaningful active composition-of-matter exclusivity |
Molindone has a narrower market than newer atypical antipsychotics such as risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone. It is generally considered an alternative treatment rather than a first-line commercial product.
When did molindone lose exclusivity?
Molindone lost meaningful market exclusivity decades ago. The original Moban approval dates to the 1970s, placing any original composition-of-matter patent protection well outside the current commercial period. Generic molindone products have been available through ANDA approvals and abbreviated regulatory pathways.
The product’s commercial profile reflects the normal lifecycle of an older generic:
| Lifecycle stage |
Approximate period |
Market effect |
| Original branded development and launch |
1970s |
Premium pricing and physician familiarity |
| Brand maturity |
1980s-1990s |
Competition from other antipsychotics |
| Generic entry |
Primarily late 1990s onward |
Rapid price erosion |
| Brand withdrawal or reduced availability |
Later commercial period |
Product becomes dependent on generic suppliers |
| Current mature-generic phase |
2010s onward |
Low volume, low pricing, limited manufacturer investment |
Exact historical launch, discontinuation, and generic-entry dates vary by product identifier and manufacturer. The commercially relevant conclusion is consistent: molindone is no longer protected by meaningful market exclusivity.
What patents protect molindone hydrochloride?
No active patent estate appears to provide material protection for the molindone hydrochloride active ingredient in the United States. The original drug and its basic oral tablet formulation are decades old.
Composition-of-matter patents
Any composition-of-matter rights associated with molindone or its hydrochloride salt would have expired long before the current generic market. The age of the active ingredient prevents a new patent from restoring product-level exclusivity.
Formulation patents
Molindone hydrochloride tablets are conventional immediate-release oral dosage forms. There is no widely recognized commercial formulation patent covering a differentiated extended-release, long-acting injectable, transdermal, or abuse-deterrent version of molindone.
A manufacturer could pursue a new formulation patent if it developed a novel delivery system, but that would create a separate product-development opportunity rather than extend protection for existing generic tablets. The commercial case would be weak unless the formulation demonstrated a substantial clinical or adherence advantage.
Method-of-use patents
No commercially significant method-of-use patent estate is associated with the established schizophrenia indication. A new use could theoretically support patenting if it met statutory novelty and non-obviousness requirements, but no such use has created a recognized market for molindone hydrochloride.
What is the Orange Book status of molindone hydrochloride?
Molindone hydrochloride is primarily a generic product rather than an actively marketed innovator product with a commercially relevant Orange Book patent listing. The FDA Orange Book is relevant for identifying approved reference products, therapeutic equivalence information, and listed patent claims, but it does not create exclusivity for an old drug where no active patent or exclusivity period remains.
For business analysis, the key Orange Book conclusions are:
- No current new-drug exclusivity protects the molecule.
- No meaningful pediatric exclusivity protects the product.
- No active formulation exclusivity is broadly associated with standard molindone tablets.
- Generic manufacturers compete through ANDA approval, manufacturing reliability, and supply availability.
- Paragraph IV litigation risk is low because the relevant product claims are old and generic entry is not dependent on challenging a valuable current patent estate.
Are there Paragraph IV challenges to molindone hydrochloride?
Molindone hydrochloride has little current Paragraph IV litigation significance. Paragraph IV certifications are most commercially important when a generic applicant challenges an unexpired patent protecting a high-value branded drug. That situation does not characterize molindone.
Any historical Paragraph IV activity would have had limited commercial value because:
- The underlying product is old.
- The market is small relative to newer antipsychotics.
- Multiple alternative antipsychotics are available.
- Generic tablet pricing is low.
- The remaining market would not normally justify expensive patent litigation.
The absence of meaningful current Paragraph IV activity reduces litigation cost but also limits the opportunity for a first-filer or 180-day generic exclusivity strategy.
How strong is the molindone hydrochloride patent estate?
The patent estate is weak from a present-value perspective.
| Patent category |
Current strength |
Commercial implication |
| Active ingredient |
Very low |
Historical rights have expired |
| Hydrochloride salt |
Very low |
Salt form is long established |
| Immediate-release tablet |
Low |
Conventional generic formulation |
| Manufacturing process |
Low to moderate in isolation |
Process claims would not block standard generic supply broadly |
| New delivery system |
Theoretical |
Requires new clinical and regulatory investment |
| Method of use |
Low |
No dominant patented indication identified |
| Data or regulatory exclusivity |
None of material duration |
No meaningful barrier to ANDA competition |
Process patents could create limited manufacturing friction if a supplier relied on a narrowly claimed route. They would not ordinarily prevent other manufacturers from using alternative processes, sourcing active pharmaceutical ingredient from another supplier, or qualifying a different manufacturing route.
What is the FDA regulatory status of molindone hydrochloride?
Molindone hydrochloride has an established FDA regulatory pathway as an oral antipsychotic. Generic versions are approved through ANDAs demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference product.
The regulatory burden is lower than for a new antipsychotic because:
- The active ingredient has an established safety and efficacy history.
- The dosage form is conventional.
- Generic applicants do not repeat the full clinical development program required for an NDA.
- Manufacturing, quality, stability, labeling, and bioequivalence remain the central requirements.
The principal regulatory risks are commercial rather than scientific. A manufacturer must maintain cGMP compliance, source qualified active ingredient, meet dissolution and stability specifications, and avoid supply interruptions.
What is the competitive landscape for molindone?
Molindone competes in a broad antipsychotic market but has a small niche within the typical-antipsychotic segment.
Direct and therapeutic competitors
| Product |
Position relative to molindone |
| Haloperidol |
Low-cost typical antipsychotic with stronger historical utilization |
| Fluphenazine |
Generic typical antipsychotic used in oral and injectable forms |
| Chlorpromazine |
Older low-cost alternative with broader historical use |
| Perphenazine |
Generic phenothiazine with continued formulary presence |
| Risperidone |
Low-cost atypical with substantially broader use |
| Olanzapine |
Large generic atypical market |
| Quetiapine |
Large generic atypical market |
| Aripiprazole |
Broad use and multiple dosage forms |
| Paliperidone palmitate |
Long-acting injectable option with a higher-value commercial profile |
Molindone lacks the dosage-form breadth and market scale of long-acting injectable antipsychotics. It also lacks the prescription volume generated by the leading generic atypical antipsychotics.
What is the financial trajectory for molindone hydrochloride?
The financial trajectory is best described as long-term erosion followed by stabilization at a low generic revenue base.
Historical trajectory
The original branded product would have generated its highest pricing before generic competition and before the expansion of atypical antipsychotics. After generic entry, the product experienced the usual combination of:
- Lower average selling prices.
- Reduced physician preference.
- Formulary substitution.
- Fewer active manufacturers.
- Lower promotional spending.
- Reduced inventory value.
- Greater sensitivity to supply interruptions.
Current revenue profile
No major public company reports molindone hydrochloride revenue as a separate material line item. It is generally embedded within broader generic or hospital-product sales. Public financial filings therefore do not support a reliable standalone market-size estimate.
A manufacturer’s molindone revenue would depend primarily on:
- Number of active competitors.
- Wholesale acquisition cost and contract pricing.
- Medicaid and commercial reimbursement.
- Hospital or institutional purchasing.
- Product availability.
- Manufacturing scale.
- API cost and minimum batch economics.
The product is unlikely to be a meaningful revenue driver unless a supplier temporarily becomes one of few available manufacturers. Even then, supply-driven price increases would likely be constrained by generic substitution and buyer resistance.
What generic entry risks exist for molindone hydrochloride?
The main risk is not a new entrant challenging a valuable patent. It is continued price pressure and potential market exit.
Generic manufacturers
Molindone may be supplied through a changing group of ANDA holders, contract manufacturers, and distributors. Product availability can vary by strength, package size, and manufacturer. Older generic products frequently experience changes in marketing status that do not reflect a change in clinical value.
Generic launch scenarios
| Scenario |
Probability |
Commercial effect |
| Additional generic entrant |
Moderate but economically limited |
More price pressure and lower supplier share |
| Existing supplier exits |
Moderate over time |
Potential shortage or temporary price increase |
| Stable multi-source supply |
Possible |
Low prices and limited manufacturer margins |
| Branded relaunch |
Low |
Requires substantial differentiation or supply disruption |
| New formulation launch |
Low |
High development cost relative to market size |
| Long-acting injectable development |
Very low |
Large clinical, manufacturing, and commercial investment |
The most credible commercial event is a supply change rather than a major product launch.
What manufacturing and intellectual-property barriers affect the market?
Manufacturing barriers are modest but can still influence short-term availability. Molindone hydrochloride is a small-molecule generic, so the principal barriers are operational:
- Reliable API sourcing.
- Validated tablet compression and coating processes.
- Stability data across marketed strengths.
- Packaging and serialization compliance.
- Low-volume production economics.
- Maintaining inventory despite limited demand.
The product does not present the cold-chain, cell-line, device, or complex biologic manufacturing barriers associated with biosimilars. It also has no biosimilar pathway because molindone is a small molecule regulated as a conventional drug.
A process patent or supplier-specific manufacturing constraint could affect an individual company. It would not normally establish durable market exclusivity across the category.
Which companies are most exposed to molindone hydrochloride?
Exposure is likely fragmented among generic manufacturers and distributors. The drug is not known to be a material product for the large diversified pharmaceutical companies that report revenue by major brands or therapeutic franchises.
Potential exposure is highest for:
- Small generic manufacturers with narrow product portfolios.
- Contract manufacturers producing low-volume hospital and institutional drugs.
- Distributors holding limited inventory.
- Suppliers with an ANDA but few competing approved products.
- Companies that become temporary sole or dual suppliers.
For an acquiring company, molindone should be valued as a low-revenue portfolio filler, not as a platform asset. Its strategic value could increase only if bundled with a broader generic portfolio, manufacturing capacity, or hospital channel.
What licensing deals and settlement agreements affect molindone?
No major publicly reported licensing transaction or patent settlement is associated with molindone hydrochloride’s current market. The product’s age, generic status, and limited revenue reduce the incentive for branded-generic licensing structures.
A commercial agreement could still cover:
- Contract manufacturing.
- API supply.
- Distribution rights.
- ANDA transfer.
- Product portfolio divestiture.
- Short-term shortage supply.
These arrangements would be operational transactions rather than exclusivity-driven deals.
What is the outlook for molindone hydrochloride?
Molindone hydrochloride should remain available as a low-volume generic where manufacturing remains economically viable. Its long-term outlook is stable to declining in prescription demand, with occasional availability volatility.
The product has:
- Minimal patent risk.
- Minimal biosimilar risk.
- Low regulatory development risk for standard tablets.
- High price competition.
- Limited market expansion potential.
- Moderate supply-continuity risk.
- Low standalone revenue significance.
A financially attractive opportunity would require an unusual condition, such as a temporary shortage, a low-competition strength, an acquisition at a very low transfer price, or integration into an existing generic manufacturing network.
Key Takeaways
- Molindone hydrochloride is a mature generic typical antipsychotic with limited commercial growth.
- The original Moban product has no meaningful remaining market exclusivity.
- Standard molindone tablets have no commercially important active patent estate.
- Current Paragraph IV and patent-litigation risk is low.
- There is no biosimilar risk because molindone is a conventional small-molecule drug.
- Public companies generally do not disclose standalone molindone revenue.
- The principal commercial risk is supplier withdrawal or shortage, not branded patent enforcement.
- New formulation or injectable development would require investment disproportionate to the existing market.
- Molindone is more relevant as a low-volume portfolio product than as a strategic growth asset.
Frequently Asked Questions
Is molindone hydrochloride still available in the United States?
Generic molindone hydrochloride tablets have been marketed in the United States, although availability can vary by strength, manufacturer, distributor, and time period.
Does molindone hydrochloride have an active Orange Book patent?
No commercially significant active Orange Book patent is generally associated with standard molindone hydrochloride tablets.
Can a company obtain new patents on molindone hydrochloride?
A company could seek patents on a genuinely novel formulation, manufacturing process, or method of use. Such patents would not restore exclusivity for existing immediate-release tablets.
Is molindone hydrochloride a candidate for a long-acting injectable?
Technically, a long-acting formulation could be developed, but the clinical, regulatory, manufacturing, and commercial investment would be substantial relative to the established tablet market.
What would cause molindone hydrochloride prices to increase?
A reduction in the number of active suppliers, API shortages, manufacturing failures, regulatory action, or a temporary product shortage could increase prices. New patent protection is unlikely to be the cause.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Electronic Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
National Library of Medicine. (n.d.). DailyMed: Molindone hydrochloride tablet labeling. https://dailymed.nlm.nih.gov/dailymed/
-
National Institute of Mental Health. (n.d.). Mental health medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
